We are live on ! Find out more
TBPH icon

Theravance Biopharma
TBPH

98 hedge funds and large institutions have $770M invested in Theravance Biopharma in 2016 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 46 increasing their positions, 18 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

360% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 5

156% more repeat investments, than reductions

Existing positions increased: 46 | Existing positions reduced: 18

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

46% more capital invested

Capital invested by funds: $525M → $770M (+$244M)

21% more funds holding

Funds holding: 81 → 98 (+17)

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $79K

Holders
98
Holders Change
+17
Holders Change %
+20.99%
% of All Funds
2.61%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.08%
New
23
Increased
46
Reduced
18
Closed
5
Calls
–
Puts
$79K
Net Calls
-$79K
Net Calls Change
-$270K

Top Buyers

Rank Fund Capital Flow
1
WIM
Woodford Investment Management
United Kingdom
+$41.2M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$29.3M
3
CAM
Cormorant Asset Management
Massachusetts
+$24.2M
4
BG
Baupost Group
Massachusetts
+$18.4M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$10.7M

Top Sellers

Rank Fund Capital Flow
1
O
OppenheimerFunds
New York
-$9.73M
2
AC
Armistice Capital
New York
-$7.52M
3
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$4.99M
4
Northern Trust
Northern Trust
Illinois
-$3.52M
5
RA
Royce & Associates
New York
-$2.09M
Name Holding Trade Value Shares
Change 		Change in
Stake
CS
26
Credit Suisse
Switzerland
$2.79M +$411K +19,043 +18%
BIM
27
Bogle Investment Management
Massachusetts
$2.62M +$2.49M +115,503 New
Charles Schwab
28
Charles Schwab
California
$2.58M +$637K +29,512 +35%
Boston Partners
29
Boston Partners
Massachusetts
$2.17M +$70.6K +3,269 +4%
California Public Employees Retirement System
30
California Public Employees Retirement System
California
$1.93M -$58.3K -2,700 -3%
California State Teachers Retirement System (CalSTRS)
31
California State Teachers Retirement System (CalSTRS)
California
$1.73M +$336K +15,542 +26%
TA
32
Teachers Advisors
New York
$1.32M +$184K +8,505 +17%
PAMU
33
Pictet Asset Management (UK)
United Kingdom
$1.31M -$493K -22,826 -29%
AllianceBernstein
34
AllianceBernstein
Tennessee
$1.31M +$542K +25,100 +77%
D.E. Shaw & Co
35
D.E. Shaw & Co
New York
$1.29M -$4.99M -230,991 -80%
Swiss National Bank
36
Swiss National Bank
Switzerland
$1.22M +$192K +8,900 +20%
NSEDCP
37
NJ State Employees Deferred Compensation Plan
New Jersey
$1.12M – – –
TC
38
TFS Capital
Pennsylvania
$1.08M +$1.03M +47,803 New
Deutsche Bank
39
Deutsche Bank
Germany
$1.08M +$156K +7,218 +18%
EA
40
Emerald Acquisition
Washington
$1.05M +$996K +46,124 New
OWIM
41
Old West Investment Management
California
$977K +$90.5K +4,193 +11%
Dimensional Fund Advisors
42
Dimensional Fund Advisors
Texas
$976K -$10.2K -474 -1%
ProShare Advisors
43
ProShare Advisors
Maryland
$903K +$179K +8,280 +26%
RhumbLine Advisers
44
RhumbLine Advisers
Massachusetts
$772K -$167K -7,711 -18%
EI
45
EAM Investors
California
$766K +$729K +33,758 New
Morgan Stanley
46
Morgan Stanley
New York
$745K +$539K +24,983 +320%
BG
47
BlackRock Group
United Kingdom
$718K -$3.46K -160 -0.5%
NFA
48
Nationwide Fund Advisors
Ohio
$649K +$217K +10,059 +54%
New York State Common Retirement Fund
49
New York State Common Retirement Fund
New York
$629K – – –
State Board of Administration of Florida Retirement System
50
State Board of Administration of Florida Retirement System
Florida
$578K +$17.6K +815 +3%
1
2
3 4

TBPH Hedge Fund Activity: Q2 2016 in Review

98 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Theravance Biopharma (TBPH) for Q2 2016, worth a combined $770M — up 46% from $525M a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new TBPH positions and 5 closed out — a net gain of 18 holders — while 46 added to existing stakes and 18 trimmed.

The largest buyer was Woodford Investment Management, adding an estimated $41.2M. The largest seller was OppenheimerFunds, cutting an estimated $9.73M.

  • 98 institutional investors held Theravance Biopharma (TBPH) as of Q2 2016, up from 81 in Q1 2016.
  • Funds reported $770M of Theravance Biopharma stock for Q2 2016, up 46% quarter-over-quarter.
  • 23 funds opened new Theravance Biopharma positions in Q2 2016 and 5 closed out, a net change of +18 holders.
  • The largest Theravance Biopharma buyer in Q2 2016 was Woodford Investment Management, an estimated $41.2M added.
  • The largest Theravance Biopharma seller in Q2 2016 was OppenheimerFunds, an estimated $9.73M sold.

Based on aggregated 13F filings for Q2 2016.